A Phase 1 relative bioavailability study assessing AL001 for dementia related to Alzheimer's disease
Latest Information Update: 04 May 2022
At a glance
- Drugs Lithium cocrystal Alzamend Neuro (Primary) ; Lithium
- Indications Alzheimer's disease; Cognition disorders; Dementia
- Focus First in man; Pharmacokinetics
Most Recent Events
- 28 Apr 2022 Status changed from recruiting to completed according to BitNile Holdings media release.
- 28 Apr 2022 According to an Alzamend Neuro media release, Alzamend Neuro announces Dollar 4 million additional investment from Digital Power lending upon completion of this trial
- 28 Mar 2022 According to an Alzamend Neuro media release, Alzamend announced that it has received the full data set from this Phase 1 clinical trial for AL001, full data demonstrate AL001 in plasma is bioequivalent to the marketed lithium carbonate product